{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aczone+5%25+gel",
    "query": {
      "intervention": "Aczone 5% gel"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aczone+5%25+gel&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-16T16:19:49.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00243542",
      "title": "Phase IV Study to Gather More Information About the Safety of ACZONE Gel, 5% in Treating Subjects With Acne Who Have G6PD Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "ACZONE Gel, 5%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2005-11",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 29,
      "location_summary": "Birmingham, Alabama • San Diego, California • San Francisco, California + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00243542"
    },
    {
      "nct_id": "NCT01931150",
      "title": "Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cetuximab-induced Papulopustular (Acneiform) Rash Who Have",
        "Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Topical Dapsone 5% Gel",
          "type": "DRUG"
        },
        {
          "name": "Moisturizer",
          "type": "OTHER"
        },
        {
          "name": "oral antibiotics",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2013-08",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-01-13",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01931150"
    },
    {
      "nct_id": "NCT00835198",
      "title": "Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone; Tretinoin",
          "type": "DRUG"
        },
        {
          "name": "Tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 163,
      "start_date": "2008-12",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2011-10-31",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 1,
      "location_summary": "Strongsville, Ohio",
      "locations": [
        {
          "city": "Strongsville",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00835198"
    },
    {
      "nct_id": "NCT01773122",
      "title": "Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone Formulation A",
          "type": "DRUG"
        },
        {
          "name": "Dapsone Formulation B",
          "type": "DRUG"
        },
        {
          "name": "Dapsone Formulation C",
          "type": "DRUG"
        },
        {
          "name": "Dapsone 5% Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "16 Years to 35 Years"
      },
      "enrollment_count": 77,
      "start_date": "2013-01-21",
      "completion_date": "2013-05-05",
      "has_results": true,
      "last_update_posted_date": "2019-04-24",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 1,
      "location_summary": "College Station, Texas",
      "locations": [
        {
          "city": "College Station",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01773122"
    },
    {
      "nct_id": "NCT00834210",
      "title": "Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone",
          "type": "DRUG"
        },
        {
          "name": "Tazarotene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 171,
      "start_date": "2008-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2011-10-31",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 1,
      "location_summary": "Fremont, California",
      "locations": [
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00834210"
    },
    {
      "nct_id": "NCT02865005",
      "title": "Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone 5.0% Gel (SEEGPharm)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Dapsone 5.0% Gel (Allergan)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Seegpharm S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 2361,
      "start_date": "2016-02",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2016-12-20",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 35,
      "location_summary": "Encino, California • Fullerton, California • La Mesa, California + 29 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02865005"
    },
    {
      "nct_id": "NCT00343187",
      "title": "A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rash",
        "Non-small-Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ACZONE (dapsone) Gel, 5%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2006-06",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Hershey, Pennsylvania • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343187"
    },
    {
      "nct_id": "NCT01231334",
      "title": "A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Dapsone plus Adapalene",
          "type": "DRUG"
        },
        {
          "name": "Clindamycin/benzoyl peroxide plus Adapalene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 286,
      "start_date": "2010-08",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2012-07-27",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 1,
      "location_summary": "Miramar, Florida",
      "locations": [
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01231334"
    },
    {
      "nct_id": "NCT00964366",
      "title": "Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "clindamycin and benzoyl peroxide",
          "type": "DRUG"
        },
        {
          "name": "Dapsone gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 53,
      "start_date": "2009-07",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 1,
      "location_summary": "Broomall, Pennsylvania",
      "locations": [
        {
          "city": "Broomall",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00964366"
    },
    {
      "nct_id": "NCT00249782",
      "title": "A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Vehicle control, 2x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 2x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 1x/day",
          "type": "DRUG"
        },
        {
          "name": "MetroGel® (metronidazole gel), 1.0% 1x/day",
          "type": "DRUG"
        },
        {
          "name": "ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2005-11",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2011-05-30",
      "last_synced_at": "2026-09-16T16:19:49.455Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fremont, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00249782"
    }
  ]
}